CSF3 and anaphylaxis: We did not observe any life-threatening/significant sudden deterioration/anaphylaxis after use of filgrastim (G-CSF).<h4>Conclusions</h4>Filgrastim (G-CSF) use in immunocompetent children with sepsis-induced MOFS is safe, and a 2-dose of filgrastim (G-CSF) for three days has poor efficacy in the reduction of mortality and did not show significant change in frequency of HAI, TNF-α levels, and pSOFA scores.